Literature DB >> 10962315

Is scrotal violation per se a risk factor for local relapse and metastases in stage I nonseminomatous testicular cancer?

F T Aki1, C Y Bilen, M I Tekin, H Ozen.   

Abstract

OBJECTIVES: To determine the risk of local recurrence and relapse in patients with Stage I nonseminomatous testicular cancer with scrotal violation.
METHODS: From 1983 to 1998, 75 patients with clinical Stage I nonseminomatous testicular cancer who were initially treated with orchiectomy and surveillance alone were retrospectively reviewed.
RESULTS: Of 75 patients with Stage I nonseminomatous testicular cancer, 13 had scrotal violation. The surgical margins and the spermatic cords were free of tumor in all patients. Five patients (38%) in the scrotal violation group and 17 patients (27%) in the inguinal orchiectomy group experienced relapses. The difference was not significant (P = 0.41). Local recurrence was not observed in either group. All relapses, except one in the standard inguinal orchiectomy group, were treated successfully with chemotherapy and postchemotherapy surgery, if needed. The progression rate and survival were not significantly different between the two groups.
CONCLUSIONS: Scrotal violation without positive surgical margins and tumor spillage does not adversely affect relapse rate and survival. Therefore, scrotal violation per se is not an exclusion criterion for the surveillance-only policy in patients with Stage I nonseminomatous testicular germ cell cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10962315     DOI: 10.1016/s0090-4295(00)00692-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  Scrotal recurrence of germ cell tumour in a non-violated scrotum.

Authors:  Jenny Li; Nicholas Power
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

Review 2.  Treatment of stage I testicular germ-cell tumors.

Authors:  Jorge Aparicio; J R Germà
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.